• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
AGLE

AGLE

Aeglea BioTherapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD12.01

+0.75 (+6.66%)

Company Profile

CEO

Jonathan D. Alspaugh

IPO Date

2016-04-07

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$10.87

Prev. Close

$11.26

Day Low

$10.69

Day High

$12.34

52W Low

$2.66

52W High

$24.00

Market Cap

$0.05B

Volume

0.04M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

39.9%

Avg Negative

5.9%

Avg Neutral

54.0%

News Feed

Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease

PRNewsWire·7/14/2021·↑ positive

Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer

PRNewsWire·7/8/2021·↑ positive

Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria

PRNewsWire·6/24/2021·↓ negative

Aeglea BioTherapeutics: Late-Stage Enzyme Therapeutic Biotech Approaches Promising Phase 3 Data Announcement

Seeking Alpha·5/19/2021·↑ positive

Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights

PRNewsWire·5/10/2021·↑ positive

Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency

PRNewsWire·5/3/2021·↑ positive

Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021

PRNewsWire·4/1/2021·↑ positive

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

PRNewsWire·3/18/2021·↑ positive

Aeglea (AGLE) Upgraded to Buy: Here's Why

Zacks Investment Research·12/30/2020·↑ positive

Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors

PRNewsWire·12/17/2020·↑ positive